Valneva SE is a specialty vaccine company. It is focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva SE is based in Saint-Herblain, France.
Revenue (Most Recent Fiscal Year) | $165.52M |
Net Income (Most Recent Fiscal Year) | $-109.78M |
PE Ratio (Current Year Earnings Estimate) | 71.73 |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 3.40 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.07 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -64.16% |
Net Margin (Trailing 12 Months) | -65.99% |
Return on Equity (Trailing 12 Months) | -59.48% |
Return on Assets (Trailing 12 Months) | -19.17% |
Current Ratio (Most Recent Fiscal Quarter) | 1.65 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.37 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 1.04 |
Inventory Turnover (Trailing 12 Months) | 2.60 |
Book Value per Share (Most Recent Fiscal Quarter) | $2.00 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.50 |
Earnings per Share (Most Recent Fiscal Year) | $-1.57 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.58 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 69.46M |
Free Float | 59.10M |
Market Capitalization | $564.67M |
Average Volume (Last 20 Days) | 5196.65 |
Beta (Past 60 Months) | 2.25 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 14.91% |
Percentage Held By Institutions (Latest 13F Reports) | 11.39% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |